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Pulmonary Arterial Hypertension 
Affects the Rat Gut Microbiome
María Callejo1,2,3, Gema Mondejar-Parreño1,2,3, Bianca Barreira1,2,3, José L. Izquierdo-
Garcia2,4,5, Daniel Morales-Cano1,2,3, Sergio Esquivel-Ruiz1,2,3, Laura Moreno  1,2,3, Ángel 
Cogolludo1,2,3, Juan Duarte6,7 & Francisco Perez-Vizcaino1,2,3
We have analysed whether pulmonary arterial hypertension (PAH) alters the rat faecal microbiota. 
Wistar rats were injected with the VEGF receptor antagonist SU5416 (20 mg/kg s.c.) and followed 
for 2 weeks kept in hypoxia (10% O2, PAH) or injected with vehicle and kept in normoxia (controls). 
Faecal samples were obtained and microbiome composition was determined by 16S rRNA gene 
sequencing and bioinformatic analysis. No effect of PAH on the global microbiome was found (α- or 
β-diversity). However, PAH-exposed rats showed gut dysbiosis as indicated by a taxonomy-based 
analysis. Specifically, PAH rats had a three-fold increase in Firmicutes-to-Bacteroidetes ratio. Within 
the Firmicutes phylum, there were no large changes in the relative abundance of the bacterial families 
in PAH. Among Bacteroidetes, all families were less abundant in PAH. A clear separation was observed 
between the control and PAH clusters based on short chain fatty acid producing bacterial genera. 
Moreover, acetate was reduced in the serum of PAH rats. In conclusion, faecal microbiota composition is 
altered as a result of PAH. This misbalanced bacterial ecosystem might in turn play a pathophysiological 
role in PAH by altering the immunologic, hormonal and metabolic homeostasis.
Pulmonary arterial hypertension (PAH) is a progressive disease affecting the lung vasculature that is character-
ized by sustained vasoconstriction, vascular remodelling and in situ thrombosis1. It evolves into an occlusive arte-
riopathy with high resistance to blood flow, leading to right heart failure and premature death2,3. In recent years, 
altered immune and inflammatory processes are being considered as pathological hallmarks of the disease2,3. In 
addition, altered metabolism involving a switch to glycolysis, fatty acid oxidation, and production of reactive 
oxygen species are also being currently recognized in the pathogenesis of PAH4.
The human gut is colonized by a huge number of bacteria, archaea, protists, fungi and viruses, forming an 
ecological community known as the gut microbiota. The gut microbiota communicates with distal organs by 
producing numerous metabolites that may be absorbed into the systemic circulation and exert biological effects5. 
The microbiota is also responsible for the integrity of the gut barrier function. Low-grade bacterial translocation 
from the intestines into the circulation with increased plasma bacterial endotoxins (lipopolysaccharides, LPS) 
may also result from gut barrier dysfunction6. In recent years, multiple evidences point to a relationship between 
the composition of the gut microbiota and an appropriate immunologic, hormonal and metabolic homeostasis7–9. 
The changes in the composition of gut microbiota associated with disease are referred to as dysbiosis. This mis-
balanced bacterial ecosystem may be therapeutically targeted using probiotics -live strains of selected bacteria- or 
prebiotics -food components modulating the microbiota10,11.
Multiple cardiovascular, metabolic and respiratory diseases such as atherosclerosis, hypertension, heart fail-
ure, chronic kidney disease, obesity, type 2 diabetes mellitus and sleep apnoea have been linked to gut dysbio-
sis12–15. This is characterized by a microbial flora that is less diverse and less rich with an increased Firmicutes to 
Bacteroidetes ratio (F/B)6,16. Changes in short chain fatty acids (SCFA) producing bacteria are also characteristic 
of gut dysbiosis with a decrease in acetate- and butyrate-producing bacteria and an increase in lactate-producing 
bacterial populations6,8,16. Moreover, the meta-analysis of the human studies supports that supplementation with 
probiotics in disease restores the proper gut microbiota and improves disease biomarkers. For instance, probiotics 
reduce blood pressure in essential hypertensives17,18.
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Despite the gut microbiota has been suggested to affect the development of pulmonary vascular disease on a 
theoretical basis19, the microbiome has not been studied so far in the context of preclinical or clinical PAH. We 
hypothesized that the development of PAH may be associated to changes in the intestinal bacterial composition. 
Therefore, we investigated the effect of PAH on the faecal microbiome in rats using 16S rRNA metagenomics20. 
We have used a representative animal model of PAH, consisting in the combination of hypoxia plus the VEGF 
antagonist SU541621. Herein, we report that PAH is associated to gut dysbiosis, namely an increased F/B ratio. 
This represents the first, but still preliminary, evidence suggesting a possible pathophysiological role of intestinal 
bacteria in the disease.
Results
Hemodynamics and vascular remodelling. SU5416 plus hypoxia for two weeks produced the expected 
increases in systolic, diastolic and mean pulmonary arterial pressure (PAP) characteristic of PAH (Fig. 1A). This 
was associated with an increased heart rate, and a trend for reduced body weight (Fig. 1B,C). PAH animals devel-
oped a marked right ventricular hypertrophy as shown by the increased RV weight in either absolute values or 
referred to LV + S (Fig. 1D,E). In addition, animals with PAH showed arterial wall remodelling with an increased 
muscularization of the small resistance arteries (Fig. 1F,G) with increased wall thickness (Fig. 1H) and occasion-
ally early obliterated lessions were observed (Fig. 1I).
Bacterial α- and β-diversity. The number of species identified was similar in the control and PAH group 
(Fig. 2A). Shannon, Chao, Simpson and PD whole tree indexes, which represent both the richness and even-
ness of its species diversity within each sample, i.e. α-diversity, were also similar in both groups (Fig. 2B). We 
performed a tridimensional principal component analysis (PCA) of the bacterial community, which measures 
microorganism diversity between samples, i.e. β-diversity, at the level of the different taxa (phylum, class, order, 
family, genus and species), in an unsupervised manner. This analysis showed no perfect clustering of the animals 
into the control and PAH groups; e.g. Fig. 2C shows the analysis at the species level.
Taxa composition. The analysis of the phyla composition showed that Firmicutes was the most abun-
dant phylum in the rat faeces, followed by Verrucomicrobia, Bacteroidetes, Proteobacteria, Tenericutes and 
Actinobacteria (Fig. 3A). Each of these taxa represented above 0.5% of total bacteria and altogether accounted for 
98.7% and 98.8% of total bacteria in control and PAH groups, respectively. A nearly four-fold relative decrease in 
the Bacteroidetes phylum (5.7 vs 1.5%) with lower relative changes in the other most abundant phyla was found in 
the animals treated with hypoxia plus SU5416. Among the less abundant phyla, there was a ≈three-fold decrease 
in Cyanobacteria-related bacteria and Thermotogae and a ten-fold decrease in Acidobacteria. The Partial Least 
Square (PLS) loadings which indicate both the magnitude of the change and the statistical probability of the dif-
ference are shown in Fig. 3B for phyla representing >0.1% of total bacteria. The most relevant differences were 
found in the Bacteroidetes phyla. A 3-dimensional scatterplot was generated by PLSR to visualize the differences 
Figure 1. Hemodynamic and histological changes. (A) Systolic, diastolic and mean PAP, (B) Heart rate, 
(C) Body weight, (D) RV and LV+S weight, (E) Fulton index [RV/(LV+S)] and (F) percentage of arterial 
muscularization. (G) Typical hematoxilin-eosin staining of arterial sections (scale bar 50 µm), (H) Medial 
thickness, (I) An early obliterated lesion (scale bar 50 µm). Results are means ± s.e.m. of 4 animals, **p < 0.05 
versus control (Students’ t test for panels A–E and Square Chi test for panel F).
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in composition of the faecal microbial communities (Fig. 3C). A clear separation was observed between the 
control and PAH clusters. Notably, the calculated F/B, a hallmark of gut dysbiosis, was significantly increased in 
PAH (Fig. 3C).
Given the altered F/B ratio, we analysed which families of bacteria contributed to this imbalance. Regarding 
the most common families of the Firmicutes phylum, in general, there were no large changes in their relative 
abundance in the PAH compared to the control group (Fig. 4A,B) with the exception of Peptostreptococcaceae, 
which suffered a seven-fold increase (0.5 to 3.7%). In the less abundant families, there was also trend for a 
decrease (≈three-fold) in Aerococcaceae and Pasteurellaceae and a five-fold decrease in Syntrophomonadaceae.
Among the Bacteroidetes phylum, all families were decreased in PAH (from 2- to 20-fold decrease, Fig. 5A). 
Figure 5B shows the PLS loadings. The most relevant decreases at the genus level were observed in Butyricimonas 
and Odoribacter among Odoribacteraceae and Porphyromonas in Porphyromonadaceae (Fig. 5D). PLS analysis 
of the families within Bacteroidetes (Fig. 5C) clearly separated the control and PAH clusters. Bifidobacterium, a 
commonly considered beneficial genus22 that belongs to the Actinobacteria phylum, was not significant different 
(0.094 ± 0.039% in control and 0.072 ± 0.005% of total reads in PAH).
SCFA-producing bacteria and SCFA in serum. We analysed the changes in the relative abundance of 
SCFA-producing bacteria as another hallmark of gut dysbiosis (Fig. 6A) and the SCFA levels in serum (Fig. 6B).
We found a trend for reduced acetate-producing bacteria that was reproduced for all individ-
ual acetate-producing genera and also for most butyrate-producing bacteria (based on PLS loadings as 
shown in Fig. 6F). A statistically significant reduction was only observed for some acetate-producing and 
butyrate-producing genera (Student t test, Fig. 6C,D). However, an overall trend for increased butyrate-producing 
bacteria was driven by the changes in the most abundant genus Anaerostipes (Fig. 6D). Lactate-producing bac-
teria were essentially unchanged (Fig. 6A,E and F). We also analysed the serum levels of SCFA from the NMR 
spectra (Fig. 6B). Acetate was significantly decreased in serum while butyrate levels were not detected in the NMR 
Figure 2. Microbial richness and diversity in PH and Principal Coordinate analysis (PCA). (A) Number of 
species identified. (B) α-diversity in rats in control and PAH rats measured by the Shannon, Chao, Simpsons 
and PD whole tree indexes. Results are means ± s.e.m. of 4 animals. (C) Unsupervised PCA were carried out 
to analyse the differences between control and PAH groups. Each principal component describes most of the 
variation between samples.
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spectra. In contrast, there was increased serum levels of lactate (P < 0.01) in PAH vs control animals (Fig. 6B). The 
PLS analysis clearly separated the control and PAH clusters based on SCFA-producing bacteria (Fig. 6G).
Discussion
The role of gut dysbiosis in the pathogenesis of many diseases, including diabetes mellitus, obesity, cancer, psy-
chiatric, respiratory and cardiovascular disorders is rapidly emerging. In this study, we present the first evidence 
of changes in the microbiota in a small sample of rats during the early phases of PAH. Notably, we found an 
increased F/B that is considered the hallmark of gut dysbiosis, in a rat model of PAH. We also found some specific 
changes in several taxa, which reproduce the changes previously observed associated to other cardiovascular and 
metabolic diseases.
Figure 3. Phyla composition. (A) Composition of the most abundant bacterial phyla (>0.01%) expressed as 
a percent of total bacteria (means ± s.e.m. of 4 animals). The inset shows the pie charts for control and PAH. 
(B) PLS loadings (data shown for phyla representing >0.1% of total bacteria) highlight variable significance 
to discriminate between PAH and control samples in PLS scores. (C) Tridimensional PLS scores plot. (D) The 
Firmicutes to Bacteroidetes ratio (F/B ratio) was calculated as a biomarker of gut dysbiosis (means ± s.e.m., 
n = 4, *p = 0.04 vs control with student’s t-test).
Figure 4. Bacterial families within the Firmicutes phylum. (A) Composition of the most abundant bacterial 
families (>0.01%) expressed as a percent of total bacteria in control and PAH rats (means ± s.e.m. of 4 animals, 
*p < 0.05 vs control with student’s t-test). (B) PLS loadings (data shown for phyla representing >0.1% of total 
bacteria) highlight variable significance to discriminate between PAH and control samples in PLS scores. (C) 
Tridimensional PLS scores plot.
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We have used the animal model of PAH of hypoxia plus SU5416, which best conforms to human PAH21. At 
two weeks, it develops a clear increase in PAP at the threshold values for clinical diagnosis and strong right ven-
tricular hypertrophy and arterial remodelling. We deliberately chose this time to analyse the early changes in the 
Figure 5. Bacterial families within the Bacteroidetes phylum. (A) Composition of the bacterial families 
expressed as a percent of total bacteria in control and PAH rats (means ± s.e.m. of 4 animals, *p < 0.05 vs 
control with student’s t-test) (B) PLS loadings (data shown for phyla representing >0.1% of total bacteria) 
highlight variable significance to discriminate between PAH and control samples in PLS scores. (C) 
Tridimensional PLS scores plot. (D) Composition of the species within the Odoribacteraceae family and 
Porphyromonas (means ± s.e.m. of 4 animals, *p < 0.05 vs control with student’s t-test).
Figure 6. SCFA and SCFA-producing bacteria. (A) Composition of the acetate-, butyrate- and lactate-
producing bacteria in control and PAH rats. Data is the sum of all SCFA-producing genera expressed as a percent 
of total bacteria (means ± SEM of 4 animals). (B) Acetate, butyrate and lactate in rat serum (AU = arbitrary 
units, nd = not detected, n = 4, *p < 0.05 vs control student’s t-test). (C–E) Most abundant acetate-, butyrate- 
and lactate-producing genera (means ± s.e.m. of 4 animals, *p < 0.05 vs control with student’s t-test).  
(F) PLS loadings (data shown for phyla representing >0.1% of total bacteria) highlight variable significance  
to discriminate between PAH and control samples in PLS scores. (G) Tridimensional PLS scores plot.
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microbiota, which might play a pathophysiological role in the development of the pathology rather than being 
a consequence of the long-term disease. Longer exposure leads to further disease worsening. For instance, at 
baseline and after the second and the third week of treatment, mPAP increases from ≈13 to 24 (present data) and 
45 mm Hg (authors unpublished data), respectively. This time-course is similar to the one shown in the original 
report of the model by Taraseviciene-Stewart et al.23 and consistent with RV pressure values of ≈30, 60 and 90 mm 
Hg, respectively, in Oka et al.24. Likewise, the Fulton indexes as a measure of RV hypertrophy were ≈0.25, 0.45 
and 0.65, respectively, in our hands and ≈0.3, 0.5 and 0.7, respectively, in Oka et al.24.
The Shannon, Simpsons, Chao and PD whole tree indexes and the PCA plot showed no apparent change in 
α- and β-diversity in controls and PAH rats. This indicates that there is no global differences in the microbiota, 
most taxa were unchanged. In contrast, other diseases have found reduced richness and diversity6,16. However, the 
most important and recognized biomarker of dysbiosis, the F/B, was significantly increased in PAH. This ratio has 
been reported to be modified in multiple pathological conditions in both human and animal models. In systemic 
hypertension increased F/B has been found in animal models of disease, including spontaneously hyperten-
sive rats, deoxycorticosterone-salt- and angiotensin II-induced hypertension, as well as in essential hypertensive 
patients16,25.
We also evaluated which subtaxa contributed to the alteration of Firmicutes and Bacteroidetes. Notably, all 
families from the Bacteroidetes phylum were decreased (from 2 to 10-fold decrease). Odoribacteraceae may be of 
special interest because several species within this family belonging to the genera Odoribacter and Butyricimonas 
have been reported to be depleted in overweight and obese pregnant women with high blood pressure, in sed-
entary mice, liver injury and multiple sclerosis26–28. In contrast to the present report, Odoribacter was found to 
be increased in mice with intermittent hypoxia29. Among Firmicutes, we found minor absolute changes, with 
an overall trend for an increase in bacterial reads. Peptostreptococcaceae, which suffered the largest absolute 
increase, is a family of Gram-positive bacteria that is over-represented in the guts of patients and mice with 
colorectal and oral cancer30,31.
Dietary fibre is fermented in the colon by commensal bacteria, leading to the release of the SCFAs, acetate, 
butyrate, and lactate, which may be absorbed into the circulation and interact with G protein-coupled olfactory 
receptors in the gut epithelium and immune cells32. Besides the changes in taxonomic categories, gut dysbiosis 
associated to cardiovascular disease is characterized by a decrease in acetate- and butyrate-producing bacteria 
and an increase in lactate-producing bacterial populations6,8,16. We found no significant changes in the sum of 
butyrate- or lactate-producing bacteria but a trend for reduced acetate-producing bacteria was found in PAH. 
A clear separation was observed between the control and PAH clusters based on short chain fatty acid pro-
ducing bacterial genera. We also analyzed the levels of the three SCFA in serum of the PAH rats and controls 
by quantifying the NMR spectra. We found that acetate was reduced in the serum of PAH rats. This change 
parallels the observed differences in acetate-producing genera. It is therefore tempting to speculate that the 
observed serum changes are secondary to the different bacterial composition. However, our experiments cannot 
rule out that the observed changes in serum SCFA are generated by the host metabolism. In fact, lactate was 
increased in the serum of PAH rats, which is expected as a result of the hypoxic environment in the host cells. 
Interestingly, acetate supplementation or an intervention with fibre to restore acetate production in mice with 
mineralocorticoid-dependent hypertension significantly reduced systolic and diastolic blood pressures, cardiac 
fibrosis, and left ventricular hypertrophy25. These protective effects seem to be related to the regulation of key 
pathways and genes involved in cardiovascular health, including the transcription factor Egr1, a master regulator 
of cardiovascular disease33,34 which has also been reported to play a role in PAH35.
Interestingly, there is certain parallelism between factors affected by gut dysbiosis and those involved in the 
pathophysiology of PAH. First, it is now well established that Th17 cell development in the gut is specifically 
impacted by commensal bacteria36. Th17 cell expansion originated in the intestine is associated with gut dysbiosis 
(higher F/B ratio) in several pathologies such as multiple sclerosis37 and lupus erythematosus38. A characteristic 
increase in peripheral Th17 cells and the Th17-produced cytokine IL-17 and a decrease in Treg cells is common 
to all forms of PAH and contributes to the development and the progression of the disease39,40. Second, gut micro-
biota is also a key regulator of Tph1 transcription (the gene encoding for the rate limiting enzyme in serotonin 
synthesis) in enterochromaffin cells which supplies the platelets of serotonin41. On the other hand, clinical and 
experimental PAH is associated with up-regulation of Tph1 gene transcripts as well as a rise in platelet-rich ser-
otonin21,42. Third, gut dysbiosis leads to low grade commensal bacterial translocation6,7 with increased plasma 
bacterial LPS, the main ligand for toll-like receptor 4 (TLR4). This innate immune receptor has been reported to 
play a key role in the pathogenesis of pulmonary hypertension43. Therefore, there might be a pathophysiological 
link between gut dysbiosis and PAH that involves the upregulation of Egr1, Th17 polarization, elevation of plasma 
serotonin and TLR4 activation.
The mechanism of how PAH induces gut dysbiosis remains to be determined. It has been reported that the 
sympathetic nervous system, via beta-adrenoceptor activation, in the gut compromises its barrier function, and 
it is capable of altering the microbiota44,45. Interestingly, PAH patients and animal models (including chronic 
hypoxia plus SU5416-induced PAH) have high sympathetic activity and circulating catecholamine levels46,47, 
which is strongly related to mortality48. Therefore, it seems reasonable to tentatively propose sympathetic over-
stimulation as a mechanism for PAH-induced gut dysbiosis. If this is the case, neurohumoral activation might 
exert deleterious effects in PAH not only by adrenergic receptor stimulation on the heart and pulmonary vessels 
but also on the splachnic circulation. However, we cannot rule out that the effects of hypoxia and SU5416 may 
not be limited to the pulmonary vasculature and could impact directly on other tissues, including the gut epithe-
lium and/or the mesenteric vasculature, leading to gut dysbiosis. Moreover, we cannot exclude that the gut is a 
primary target of hypoxia and/or SU5416 and that the subsequent changes in the microbiota secondarily trigger 
or potentiate PAH. In addition, our experiments do not clarify whether the changes in the microbiota are induced 
by hypoxia, SU5416 or the combination of both. SU5416 itself induces mild pulmonary hypertension23 and lung 
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cell apoptosis and emphysema49. A possible strategy to address these issues could be to treat animals with SU5416 
by inhalation to minimize the direct systemic effects. However, to our knowledge, there are no reports using this 
administration route for this drug.
In conclusion, the present study is the first one showing that PAH affects the gut microbiota. Further research 
is required to determine whether dysbiosis plays a pathophysiological role in the development of PAH or if it is 
just an epiphenomenon. If the former is true, a new therapeutic window will be opened in PAH. Several ther-
apeutic strategies can be used to restore the microbiota in disease10,11,17,25, including specific bacterial strains 
(probiotics), fibre and dietary polyphenols (i.e. prebiotics), faecal transplantation, antibiotics, beta-adrenergic 
antagonists45 or to replace the deficit in specific SCFAs (e.g. acetate)25.
Material and Methods
Animals. Pathogen-free male Wistar rats (300 g, 11–12 weeks of age) were obtained from Envigo (Barcelona, 
Spain). All experimental procedures utilizing animals were carried out according to the Spanish Royal Decree 
1201/2005 and 53/2013 on the Care and Use of Laboratory Animals and approved by the institutional Ethical 
Committees of the Universidad Complutense de Madrid (Madrid, Spain) and the regional Committee for 
Laboratory Animals Welfare (Comunidad de Madrid, Ref. number PROEXO-301/16).
Model of PAH. PAH was induced in rats by a single subcutaneous injection of SU5416 (20 mg/kg; Tocris, 
UK) and then maintained in hypoxia for two weeks21. Hypoxic animals (n = 4) breathed a gas mixture (N2 and 
room air) in a semi-closed chamber where oxygen was continuously monitored by an oxygen sensor (DrDAQ, 
PicoTechnology, UK) to maintain 10% O2. Control animals (n = 4) were exposed to rom air (21% O2, normoxia) 
in another chamber. CO2 and water vapour produced by the animals were captured with soda lime and silica gel, 
respectively. Animals were fed normal rat chow.
Hemodynamic measurements. At the end of two weeks, rats were anesthetized (80 mg/kg ketamine and 
8 mg/kg xylacine i.p.), tracheostomyzed and ventilated with room air (tidal volume 9 mL/kg, 60 breaths/min, and 
a positive end-expiratory pressure of 2 cm H2O, Nemi Scientific Inc, Medway, USA). After sternotomy, a catheter 
was placed in the pulmonary artery (PA) through the right ventricle for systolic, diastolic and mean PA pressure 
(sPAP, dPAP and mPAP) recording50. It should be noted that open-chest measurements in anaesthetized animals 
underestimate real PAP. At the end of the experiment, the right ventricle (RV) and the left ventricle plus the sep-
tum (LV + S) were dissected and weighed.
Lung histology. The left lung was inflated in situ with formol saline through the left bronchus and embed-
ded in paraffin. Lung sections were stained with haematoxylin and eosin and examined by light microscopy, and 
elastin was visualized by its green auto-fluorescence. Small arteries (25–100 mm outer diameter) were analysed 
in a blinded fashion and categorized as muscular, partially muscular or non-muscular as previously described50.
DNA Extraction, 16S rRNA Gene Amplification, Bioinformatics. For the analysis of the bacterial 
population present in the gut, faecal samples were collected from four individual animals at the end (day 14) 
of the experimental period. Bacterial genomic DNA was extracted from faecal samples using G-spin columns 
(INTRON Biotechnology) starting from 30 mg of samples resuspended in PBS and treated with proteinase K 
and RNAses. DNA concentration was determined in the samples using Quant-IT PicoGreen reagent (Thermo 
Fischer) and DNA samples (about 3 ng) were used to amplify the V3-V4 region of 16S rRNA gene51. PCR products 
(approx. 450 pb) included extension tails which allowed sample barcoding and the addition of specific Illumina 
sequences in a second low-cycle number PCR. Individual amplicon libraries were analysed using a Bioanalyzer 
2100 (Agilent) and a pool of samples was made in equimolar amounts. The pool was further cleaned, quantified 
and the concentration estimated by real time PCR (Kapa Biosystems). Finally, DNA samples were sequenced on 
an Illumina MiSeq instrument with 2 × 300 paired-end read sequencing at the Unidad de Genómica (Parque 
Científico de Madrid). Negative controls included from the beginning of the procedure were completely negative 
and therefore not included in the sequencing run. We did not carry positive controls in our experiments since 
these primers have been extensively used51. The two-step PCR amplification that we have used52 allows the suc-
cessful recovery of mock community species. Our approach to increase diversity included: (a) running different 
projects in the same run so that proximal clusters can easily start with different sequences; (b) increasing the 
percentage of PhiX174 DNA, to further increase diversity with an equilibrated shotGun DNA; and (c) dilut-
ing cluster density to suboptimal concentration for Miseq v3 runs. DNA reads were quality filtered according 
to MiSeq standard parameters (Illumina) resulting in a final output of around 150 K reads on average per rat 
(range: 90–220 K). Operational taxonomic units (OTUs) were assigned using the 16S-metagenomics workflow 
(1.0.1) associated to the Base Space Hub (Illumina). Classification was based on an Illumina-curated version of 
the GreenGenes taxonomic database which implements the Ribosomal Database Project (RDP) Classifier53. The 
Taxonomy Database (National Center for Biotechnology Information) was used for classification and nomencla-
ture. Bacteria were classified based on the SCFA end product as previously described54,55.
Serum SCFA measurements. Serum samples (40 µL) were examined by 500 MHz High-Resolution Magic 
Angle Spinning Nuclear Magnetic Resonance Bruker AMX500 spectrometer at CIC Biomagune (Donostia, 
Spain). Samples were placed into a 50-µl zirconium oxide rotor using a rinsed cylindrical insert, together with 15 µl 
0.1 mM solution Trimethylsilyl propanoic acid (TSP) in deuterium water (D2O). Standard solvent-suppressed 
spectra were acquired using a sequence based on the first increment of the nuclear Overhauser effect spectros-
copy (NOESY) pulse sequence. A number of bidimensional homonuclear and heteronuclear experiments such 
as standard gradient-enhanced correlation spectroscopy (COSY), 1H–1H total correlated spectroscopy (TOCSY), 
and gradient-selected heteronuclear single quantum correlation (HSQC) protocols were performed to carry out 
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metabolites assignments. Spectral processing was performed using the “Metabonomic” R package56. 1H NMR 
spectra were referenced to the TSP signal at 0 ppm chemical shift and normalized to total sum of the spectral 
regions. Two-dimensional spectral processing and editing was performed using MestRenova v. 11.0.3 (Mestrelab 
Research S.L., Santiago de Compostela, Spain).
Statistical analysis. The Shannon, Chao, Simpsons and PD whole tree indexes were calculated to analyse 
α-diversity using QIIME. Reads in each OUT were normalized to total reads in each sample. Only taxa with a 
percentage of reads >0.001% were used for the analysis. Data are expressed as means ± s.e.m. Statistical compari-
sons were performed using two-tailed unpaired t tests at α < 0.05 where appropriate. Unsupervised classification 
studies with Principal Components Analysis (PCA)57 were carried out to analyse the differences between groups 
for each taxonomic level. Partial Least Square (PLS) analysis was also applied to these data to identify significant 
differences between groups. PLS analysis58 is a commonly used supervised multivariate method for analysing 
high-dimensional data where PLS loadings highlight the most significant variables from the total pool. The PLS 
components are composed of so-called scores and loadings. PLS loadings contain information about the varia-
bles in the dataset highlighting the most significant variables from the total pool. PLS scores hold information 
on samples in the dataset highlighting the differences between groups. PLS analyses were performed with the 
Metabonomic package (rel.3.3.1)56 using the algorithm proposed by Ding and Gentleman59. Three PLS com-
ponents were chosen to build the model based on the percentage of variance explained, the R2, and the mean 
squared error of cross-validation graphics.
Data availability. All data of the present study are available on request.
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